H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aclaris Therapeutics (ACRS – Research Report) today and set a price target of $16.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising developments in Aclaris Therapeutics’ pipeline, particularly the progress of bosakitug in treating atopic dermatitis. The initiation of a Phase 2 trial for bosakitug, following compelling results from a previous Phase 2a trial, highlights its potential as a best-in-class therapeutic option. The trial aims to evaluate its efficacy and safety in patients with moderate-to-severe atopic dermatitis, with top-line results expected in the second half of 2026.
Additionally, Aclaris is advancing other promising programs such as ATI-2138, which is being tested for multiple indications, and the development of next-generation ITK inhibitors and bispecific antibodies. These efforts, along with strategic partnerships and ongoing trials in other therapeutic areas, suggest significant long-term upside potential for the company, supporting the Buy rating and a 12-month price target of $16.
In another report released on May 28, Leerink Partners also reiterated a Buy rating on the stock with a $7.00 price target.